Houston real estate giant cracks down on carbon emissions

seeing green

Hines, which opened its Texas Tower in 2021, is hoping to reach net-zero operational carbon by 2040. Image via Hines

Houston-based real estate giant Hines is on a mission to make its entire global portfolio free of carbon emissions.

Hines recently set a target of its 1,530 properties in 28 countries being net-zero operational carbon by 2040, including the 27.7 million square feet of space it owns or manages in the Houston area. Operational carbon refers to greenhouse gases produced by building operations.

The company says it will accomplish the net-zero goal by reducing emissions through renewable technology, and not by purchasing carbon offset credits.

Peter Epping, global head of ESG (environmental, social, and governance) at Hines, says that because the company has made its carbon-neutral plan public, “investors, developers, engineers, and building managers across our industry can use it to guide their own carbon-reduction efforts.”

Hines notes that the real estate sector emits nearly 40 percent of global carbon emissions related to energy. The World Building Council’s Net Zero Carbon Buildings Commitment calls for decarbonizing half of buildings by 2030 and all buildings by 2050.

“As the impact of climate change is becoming increasingly integrated into our lives every day, the real estate industry has a responsibility to acknowledge this growing problem and take meaningful action to reduce our collective carbon emissions,” Jeff Hines, chairman and co-CEO of Hines, says in a news release. “By seeking to achieve net-zero operational carbon without relying on offsets, Hines wants to raise the bar for sustainability and invest in a plan designed to achieve significant and tangible results.”

To achieve those results, Hines plans to:

  • Halting the use fossil fuels to power buildings in its $90.3 billion portfolio.
  • Reducing energy demand by improving building efficiencies.
  • Boosting reliance on renewable energy.
  • Using “circular systems” to reduce energy waste and enhance efficiency.
  • Promoting carbon capture.

A recent report from Houston-based law firm Vinson & Elkins underscores the economic benefits that the net-zero movement presents to commercial real estate players like Hines.

“Real estate increasingly attracts attention from sustainability-minded investors amid a wider push for ESG considerations in bond and loan markets. … Decarbonizing the real estate industry will likely require trillions of dollars of capital, but there is vast opportunity for environmentally friendly projects to access additional financing sources, often on favorable terms,” Caitlin Snelson, sustainable finance senior associate in the Houston office of Vinson & Elkins, says in a news release.

Beyond real estate, Hines’ net-zero campaign aligns with efforts to transform Houston into a net-zero industrial hub. A whitepaper published by Columbia University’s Center on Global Energy Policy declares that Houston is well-positioned to become a “best in class” net-zero hub.

According to the whitepaper, the hub “could serve as a magnet for new and emerging industries, innovators and entrepreneurs and investment in energy transition companies and resources. Failure to develop a hub could lead to loss of these benefits and opportunities.”

Consulting giant McKinsey & Co. points out that clean hydrogen is emerging as a vehicle to achieve net-zero status and says Houston could evolve into a global hub for clean hydrogen. A Houston hub that’s in place by 2050 could generate 180,000 jobs and an economic impact of $100 billion, according to McKinsey.

“With the right supportive policy frameworks, Texas could become the global leader in clean-hydrogen production, application, development, and exports with Houston at its core; the resulting thriving hydrogen community could push innovation and develop the necessary talent to conceive and deliver hydrogen projects,” McKinsey says.

Laura Hines-Pierce, 38, is the new co-CEO with her father Jeff Hines. Photo courtesy of Hines

Gerald D. Hines' granddaughter named new co-CEO of global real estate powerhouse

boss up

A global real estate juggernaut now has a new — and familiar — face in the executive office. Hines announced that Laura Hines-Pierce has been promoted to co-CEO, joining Jeff Hines, her father.

This move makes Hines-Pierce, 38, one of the youngest CEOs of a major real estate organization and one of only a few women in an often male-dominated industry.

Hines-Pierce was most recently Hines’ senior managing director in the office of the CEO since 2020, and before that, served as the firm’s transformation officer. She is credited with building the investment management platform that launched three flagship funds across the U.S. and Asia with a total current investment capacity of $4.8 billion in equity, translating to $10.8 billion in purchasing power.

Other work included integrated innovation into all areas of the business and further defined the firm’s ESG commitments, per press materials.

While serving as the firm’s transformation officer, Hines-Pierce worked with the co-heads of investment management, the global chief investment officer, and the CEO of capital markets, to refine investment strategy and acquisition efforts.

On-the-ground and grassroots work also included serving as project manager for River Point, a one-million-square-foot development in Chicago. She was also part of the OneHines Women’s Network, which focused on the company’s diversity and inclusion.

Before her Hines tenure, Hines-Pierce worked for Sotheby’s in New York. She graduated from Duke University with a BA in Economics and Art History and received her MBA from Harvard University, per her bio.

As far as next steps, Hines is keeping it in the family: plans include Hines-Pierce’s two brothers, Adam and Matthew Hines, who are expected to join her and Jeff in the office of the CEO.

“I’m proud to become co-CEO and continue the momentum we’re experiencing across the board at Hines,” said Hines-Pierce in a statement. “My father has been the catalyst for our global expansion and growth over the past three decades and I’m excited to partner with him at this pivotal moment for the firm. The pace of innovation in real estate is finally catching up with other industries; my primary focus has always been – and continues to be – positioning Hines at the forefront of those changes.”

Hines is the brainchild of real estate icon Gerald D. Hines, who passed away in 2020 at the age of 95. Gerald Hines engineered his fledgling firm from an entrepreneurial startup in Houston in 1957 into an international powerhouse that has developed, owned, and managed some of the world’s most recognizable architectural landmarks across five continents. The firm boasts nearly 1,500 buildings in 255 cities in 27 countries and some $84 billion in assets.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings